HER3-ADC

HER3-ADC is an experimental auristatin-based antibody-drug conjugate designed to target HER3-positive pancreatic cancer cells and enhance the efficacy of radiation therapy. It consists of the nonligand competing anti-HER3 antibody 9F7-F11 conjugated to monomethylauristatin E (MMAE). Upon internalization into tumor cells, HER3-ADC induces cell cycle arrest in the G2/M phase, promotes programmed cell death, and decreases clonogenic survival by increasing DNA double-strand break formation and modulating DNA damage repair. It also contributes to tumor radiosensitization by inhibiting the AKT-induced survival pathway and synergistically reducing STAT3 phosphorylation.